MORPHINE PHARMACOKINETICS AND –DYNAMICS IN HEALTHY VOLUNTEERS AND PATIENTS WITH OBESITY AND OBSTRUCTIVE SLEEP APNOEA. -AN INVESTIGATOR INITIATED, CLINICAL STUDY OF THE IMPACT OF OBESITY AND SLEEP APNOEA ON THE PHARMACOLOGY OF MORPHINE

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500779-29-00

Enrollment

140

Registered

2022-09-26

Start date

2022-12-01

Completion date

2025-12-16

Last updated

2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and Obstructive Sleep apnoea

Brief summary

The primary endpoints is the area under the curve (AUC)morphine, and maximum plasma concentration (CMAX)morphine

Detailed description

The secondary endpoints is reported stimulus intensity during the Heat, Cold, Bone and Muscle Pressure Tests, ie the quantitive sensory testing

Interventions

DRUGNALOXONE HYDROCHLORIDE

DRUGMORPHINE HYDROCHLORIDE

DRUGLIDOCAINE HYDROCHLORIDE

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The primary endpoints is the area under the curve (AUC)morphine, and maximum plasma concentration (CMAX)morphine	—

Secondary

Measure	Time frame
The secondary endpoints is reported stimulus intensity during the Heat, Cold, Bone and Muscle Pressure Tests, ie the quantitive sensory testing	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026